Interactive Strength Inc. (Nasdaq: TRNR) Wins Appeal for Continued Nasdaq Listing

August 12, 2024 7:00 AM

Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or "the Company"), maker of innovative specialty fitness equipment under the CLMBR and FORME brands, today announced that the Company received a letter stating that the Nasdaq Hearings Panel has granted the Company's request for continued listing on the Nasdaq Stock Market.As of March 31, 2024, the Company was not in compliance with Listing Rule 5550(b)(1) (the "Equity Rule") which specifies a...

Read more

Theralase(R) Release’s 2Q2024 Financial Statements

August 12, 2024 7:00 AM

Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses has released the Company's unaudited condensed consolidated interim financial statements for the six-month period ended June 30, 2024. ("Financial...

Read more

Diabetics Trust Launches New Platform to Support Students with Diabetes

August 12, 2024 4:15 AM

Diabetics Trust has introduced an innovative solution aimed at empowering students who manage diabetes, helping them improve their financial stability while navigating the demands of student life. By offering a dedicated platform where individuals can receive cash for diabetic test strips and other unused supplies, Diabetics Trust addresses a growing need within the student community. Many students, already facing the dual challenge of managing...

Read more

Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing

August 9, 2024 4:15 PM

SAN DIEGO, CA / ACCESSWIRE / August 9, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA low-dose interferon therapeutics, today announced that it has obtained exclusive licenses for a total of 10 invention patents and patent applications from Taiwan Carbon Nano Technology ("TCNT"), the Company's affiliate and product...

Read more

Xtant Medical Announces Closing of $5.0 Million Private Placement

August 9, 2024 4:05 PM

Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the closing of its previously announced $5.0 million private placement with an existing institutional investor. The Company sold 7,812,500 shares of common stock at a purchase price of $0.64 per share. After deducting fees and other estimated offering expenses, the Company...

Read more

Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024

August 9, 2024 10:00 AM

WOBURN, MA / ACCESSWIRE / August 9, 2024 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2024 on Wednesday, August 14, 2024. The results will be released after the market close on Wednesday, Aug 14 and the company will host a conference call on Thursday, August 15 at 10:00am...

Read more

MedEvolve Rated Top Revenue Cycle Management Workflow Optimization and Automation Solution, 2024 Black Book RCM Client Survey

August 9, 2024 8:00 AM

TAMPA, FL / ACCESSWIRE / August 9, 2024 / Black Book Research announces that MedEvolve has been named the top vendor for Revenue Cycle Management (RCM) workflow optimization and automation services, as recognized by clients in the Q3 2024 satisfaction survey. The survey included feedback from 1,887 providers, medical group financial system users, and business office leaders. Among over 200 core and niche RCM technology vendors, MedEvolve...

Read more

FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development Team

August 9, 2024 7:30 AM

TORONTO, ON / ACCESSWIRE / August 9, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update on its investment in Celly Nutrition Corp. ("Celly Nu"), a privately held Canadian company launching an innovative beverage product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption.On August 9, 2024, Celly Nutrition which is backed by a world-class pharmaceutical research &...

Read more

Next Health Celebrates Eight Years of Pioneering Proactive Healthcare, Commits to Continued Innovation and Growth

August 9, 2024 7:15 AM

Next Health, the pioneer of data-driven proactive healthcare, proudly celebrated its eighth anniversary with events, promotions, and reinforced commitments for long-term continued growth. Founded on the vision of improving the healthspan and extending the lifespan of its customers, Next Health is the leader in personalized, data-driven health optimization & longevity that streamlines patient access to cutting-edge services and technology either...

Read more

Cantargia Reports Progress and Strong Biomarker Data from Phase I Clinical Trial with CAN10

August 9, 2024 4:20 AM

LUND, SWEDEN / ACCESSWIRE / August 9, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported progress in the ongoing phase I clinical trial of CAN10. The independent data monitoring committee has reviewed unblinded data from study participants in the ongoing single dose part of the trial and recommended continuation to the next phase, multiple dosing in participants with psoriasis, planned to start during...

Read more

Cheyanne Mallas, CEO and Founder of The Private Suite LA, Announces the Launch of North S.T.A.R. Technologies

August 8, 2024 7:30 PM

LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / In the dynamic world of cosmetic dermatology, Cheyanne Mallas The CEO and Founder of The Private Suite LA stands out as she has carved out a distinguished career specializing in bioregenerative aesthetics, facial optimization and structural rejuvenation. She is a serial entrepreneur, angel investor and Celebrity Injector. Now, she is poised to revolutionize the industry further with her latest...

Read more

Patients for Patient Safety US to Celebrate New Patient Safety Rules on World Patient Safety Day

August 8, 2024 7:00 PM

WASHINGTON, DC / ACCESSWIRE / August 8, 2024 / As World Patient Safety Day 2024 approaches on September 17th, Patients for Patient Safety US (PFPS US) commends the U.S. Centers for Medicare and Medicaid Services (CMS) for adding a game-changing new Patient Safety Structural Measure (PSSM) to the payment and policy rules for hospitals providing services under Medicare, Medicaid and the Children's Health Insurance Program.Starting on October 1,...

Read more

StrideCare Center of Excellence Opens in Denison, Offering Comprehensive Vascular, Podiatry and Wound Care

August 8, 2024 6:55 PM

StrideCare, the largest multi-specialty medical network in Texas, announces the opening of its new StrideCare Center of Excellence in Denison, Texas. This state-of-the-art facility combines vascular, podiatry and wound care services, offering comprehensive lower extremity care to patients in Grayson County and Southern Oklahoma.Located at 4616 U.S. 75, Suite 170, Denison, Texas 75020, the clinic is easily accessible from US Highway 75 and Pool...

Read more

Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024

August 8, 2024 5:20 PM

DENVER, CO / ACCESSWIRE / August 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Conference, taking place virtually on Wednesday, August 14, 2024, and Thursday, August 15,...

Read more

Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results

August 8, 2024 4:10 PM

Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its third fiscal quarter ended June 30, 2024. The Company's Form 10-Q can be viewed at https://investors.adnas.com/sec-filings/.Third Quarter Operational Highlights and Corporate Updates:LineaRx (Therapeutic DNA Production Services)GMP roadmap execution:On schedule for the FY24...

Read more

Sonoma Pharmaceuticals Reports First Fiscal Quarter 2025 Financial Results

August 8, 2024 4:10 PM

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its first fiscal quarter ended June 30, 2024."This year marks the...

Read more

BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen

August 8, 2024 4:05 PM

LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024."We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "This success translates to over...

Read more

Avinger Reports Second Quarter 2024 Results

August 8, 2024 4:01 PM

Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the second quarter ended June 30, 2024.Second Quarter and Recent HighlightsReported second quarter 2024 revenue of $1.8 million, with a sequentially increased gross margin of 20%Streamlined operating costs...

Read more

NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines

August 8, 2024 2:15 PM

NEC Bio Therapeutics and AGC Biologics have announced a partnership to advance the production of NECVAX-NEO1, an orally delivered, bacteria-based DNA vaccine designed to target patient-specific tumor neoantigens. This important and promising collaboration aims to enhance the production of personalized cancer treatments by leveraging the biotechnology strengths of both companies.Advancing Personalized Cancer TreatmentNEC Bio Therapeutics, a...

Read more

Cosmos Health Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash; Enters $750M+ Market

August 8, 2024 1:00 PM

CHICAGO, IL / ACCESSWIRE / August 8, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has completed the registration process to commence sales in Germany...

Read more